Market Overview - The stock market is currently experiencing high valuations, with major indexes at or near all-time highs, following recent interest rate cuts by the Federal Reserve [2] - Despite the positive outlook, there is a possibility of a significant market correction by early 2026 due to elevated economic uncertainty [2] Company Analysis: AbbVie - AbbVie has a high price-to-earnings ratio of 103, but its forward earnings multiple is around 15, indicating potential growth [5] - The company is seeing strong sales from its autoimmune disease drugs Skyrizi and Rinvoq, as well as migraine therapies Qulipta and Ubrelvy, with a robust pipeline of around 50 programs in mid- or late-stage clinical development [6] - AbbVie is a Dividend King, having increased its dividend for over 50 consecutive years, with a current yield of nearly 3% [8] Company Analysis: Enterprise Products Partners - Enterprise Products Partners has demonstrated strong cash flow resilience through various economic downturns, including the financial crisis and the COVID-19 pandemic [9] - The company operates over 50,000 miles of pipeline, providing critical energy infrastructure that is largely recession-resistant, with 90% of long-term contracts including inflation escalation provisions [10] - The company has a distribution yield of 6.8% and has increased its distribution for 27 consecutive years [11] Company Analysis: Pfizer - Pfizer offers a high dividend yield of 7.15% and is committed to maintaining and growing its dividend [12] - The stock trades at a low valuation of 7.7 times forward earnings, with a PEG ratio of 0.96, suggesting it may not decline significantly even in a market correction [13] - Pfizer has a strong product lineup and a robust pipeline with 108 candidates, including 28 in late-stage testing, which should help offset anticipated sales declines from patent expirations [14]
3 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off